Filing Flows › TriSalus Life Sciences (TLSI) › Q2 2026 › vs Q1 2026
TriSalus Life Sciences (TLSI) Q2 2026 vs Q1 2026 (quarter over quarter)
TriSalus Life Sciences's revenue rose $2.5M (+28%) from $8.9M in Q1 2026 to $11.4M in Q2 2026.
TriSalus Life Sciences, Q2 2026: revenue $11.4M (+2% year over year), operating margin -86.0%, net loss $9.2M, operating cash flow −$10.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $11.4M | $8.9M | $2.5M | +28% |
| Other income, net | $630K | $10.0M | −$9.3M | -94% |
| Net loss | $9.2M | −$1.5M | $10.7M | — |
| Costs & expenses | $21.2M | $18.9M | $2.4M | +13% |
| Operating costs | $21.2M | $17.3M | $3.9M | +23% |
| Income tax | $4K | $4K | $0 | 0% |
| Cost of revenue | $1.5M | $1.2M | $278K | +23% |
| Research & development | $3.1M | $3.2M | −$79K | -2% |
| Sales & marketing | $11.4M | $7.4M | $4.0M | +54% |
| General & admin | $5.2M | $5.5M | −$292K | -5% |
| Operating cash sources | $12.9M | $9.1M | $3.8M | +42% |
| Depreciation & amortization | $136K | $135K | $1K | +0.7% |
| Share-based compensation | $2.6M | $2.5M | $144K | +6% |
| Cash used in operations | $10.1M | $6.5M | $3.6M | +56% |
| Net loss absorbed | $9.2M | −$1.5M | $10.7M | — |
| Working capital & other | $3.7M | $10.6M | −$6.9M | -65% |
Questions
How much did TriSalus Life Sciences's revenue grow quarter over quarter in Q2 2026?
TriSalus Life Sciences's revenue rose $2.5M (+28%) from $8.9M in Q1 2026 to $11.4M in Q2 2026.